Real-world application of 18F-FES PET/CT on HR + breast cancer patients with brain metastases
European Journal of Nuclear Medicine and Molecular Imaging · 2026
DOI: 10.1007/s00259-025-07657-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Shuting Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Breast Neoplasms, Brain Neoplasms, Estradiol. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Science and Technology Innovation Medical Development Foundation, Beijing Xisike Clinical Oncology Research Foundation.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: 18F-fluoroestradiol positron emission tomography/computed tomography (18F-FES PET/CT) offers a novel method for assessing whole-body estrogen receptor (ER) expression in metastatic breast cancer. Brain metastases significantly impact survival in hormone receptor positive (HR +) patients, yet the role of FES-PET in this setting remains underexplored. METHODS: We retrospectively screened 1049 patients who underwent 18F-FES PET/CT from 2012 to 2024 at Fudan University Shanghai Cancer Center. Of these, 23 HR + breast cancer patients with intracranial lesions were included and followed for a median of 21.5 months. Survival outcomes, including intracranial progression-free survival (PFS), were analyzed, and FES-related parameters measured and verified. RESULTS: Among the 23 patients, 7 (30.4%) developed intracranial symptoms, 12 (52.2%) received radiotherapy or surgery, and 16 (69.6%) received endocrine-based systemic therapy. FES-PET showed 80% concordance with MRI and 100% with pathology. Patients with the high maximum standardized uptake value (SUVmax) (≥ 1.8) demonstrated a markedly prolonged intracranial PFS compared to those with lower values (mPFS not reached vs 3.75 months, p < 0.001). ROC curve analysis established FES SUVmax as a significant predictor of intracranial progression (AUC = 0.742; 95% CI, 0.556-0.928). Multivariate analysis further identified FES SUVmax classification (HR = 7.985, 95% CI 1.214-52.506, p = 0.031) and disease-free interval (DFI) (HR = 0.033, 95% CI 0.005-0.211, p < 0.001) as the significant, independent predictors of intracranial PFS. CONCLUSION: Our results confirm the vital role of 18F-FES PET/CT as evaluation method and predictive tool for assessing intracranial disease in HR + breast cancer patients, highlighting its capacity to potentially improve personalized treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
- Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
- Center for Biomedical Imaging, Fudan University, Shanghai, 200032, China.
- Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, 200032, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. yangzhongyi21@163.com.
ORCID-Profile: Zhongyi Yang, Biyun Wang
Förderung
- National Natural Science Foundation of China
- Beijing Science and Technology Innovation Medical Development Foundation
- Beijing Xisike Clinical Oncology Research Foundation
Zitieren
APA
Li, S., Xie, Y., Liu, C., Song, S., Wang, H., Yang, Z., & Wang, B. (2026). Real-world application of 18F-FES PET/CT on HR + breast cancer patients with brain metastases. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07657-6
Vancouver
Li S, Xie Y, Liu C, Song S, Wang H, Yang Z, et al. Real-world application of 18F-FES PET/CT on HR + breast cancer patients with brain metastases. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-025-07657-6
BibTeX
@article{Li2026,
author = {Li, Shuting and Xie, Yizhao and Liu, Cheng and Song, Shaoli and Wang, Hongxia and Yang, Zhongyi and Wang, Biyun},
title = {Real-world application of 18F-FES PET/CT on HR + breast cancer patients with brain metastases},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
doi = {10.1007/s00259-025-07657-6}
}
EUVIMED